GRI is fundamentally changing the way inflammatory disease is treated with its Natural Killer T cell targeted therapies.  GRI is a highly innovative lean development company advancing a unique approach to treating some of the most debilitating diseases of our time.  NKT cells share properties of both NK and T cells, are a functional link between innate and adaptive immunity, regulate the expression of key cytokines and are critical in modulating the immune response. Our lead programs include NKT I cell inhibitors and NKT II cell modulators.